Trial Profile
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2022 Status changed from active, no longer recruiting to completed.
- 24 May 2021 Planned End Date changed from 1 Oct 2021 to 1 Nov 2021.
- 26 Jul 2018 Status changed from recruiting to active, no longer recruiting.